专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008150741A1 CONTROLLED RELEASE DOPAMINE AGONIST COMPOSITIONS 审中-公开
标题翻译：受控释放多巴胺激动剂组合物
公开(公告)号：WO2008150741A1
公开(公告)日：2008-12-11
申请号：PCT/US2008/064772
申请日：2008-05-23
申请人： DRUGTECH CORPORATION , BORTZ, Jonathan David , GRIMSHAW, Michael , ERKOBONI, David F.
发明人： BORTZ, Jonathan David , GRIMSHAW, Michael , ERKOBONI, David F.
IPC分类号： A61K9/52 , A61K9/22
CPC分类号： A61K31/428 , A61K9/2077 , A61K9/209 , A61K9/5084
摘要： The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration.
摘要翻译：本发明涉及具有多巴胺激动剂作为活性成分的多相释放口服药物制剂。多相组合物包含至少两种不同的释放组分。本发明涉及普拉克索的控释药物组合物或其药学上可接受的盐，用于每日一次给药。

2. 发明申请

WO2009018514A1 DOSAGE FORM AND METHOD OF USE 审中-公开
标题翻译：剂型及使用方法
公开(公告)号：WO2009018514A1
公开(公告)日：2009-02-05
申请号：PCT/US2008/071900
申请日：2008-08-01
申请人： DRUGTECH CORPORATION , BORTZ, Jonathan, David , GRIMSHAW, Michael
发明人： BORTZ, Jonathan, David , GRIMSHAW, Michael
IPC分类号： A01N43/00 , A61K31/553
CPC分类号： A61K31/553
摘要： Methods for treating medical conditions for which quetiapine is indicated in a subject, comprising oral administration of quetiapine or a pharmaceutically acceptable salt thereof to treat said condition; wherein the dosage form comprises a major quetiapine component in immediate-release form in a sedative effective amount, administered prior to the start of a sleep period and either (i) a minor quetiapine component in extended-release, delayed extended-release or delayed pulsed-release form, wherein substantial onset of release of quetiapine is not earlier than about 6 hours after the start of the sleep period, or (ii) a plurality of minor quetiapine components in immediate-release form, administered sequentially during a waking period following the sleep period but not earlier than about 6 hours after the start of the sleep period; said minor component or components being administered in an anxiolytic effective amount insufficient to cause an unacceptable degree of sedation.
摘要翻译：用于治疗在受试者中显示喹硫平的医学病症的方法，包括口服施用喹硫平或其药学上可接受的盐以治疗所述病症; 其中所述剂型包含镇静有效量的立即释放形式的主要喹硫平组分，在睡眠期开始之前给予，以及（i）延长释放，延迟释放或延迟脉冲中的次要喹硫平组分释放形式，其中喹硫平的释放的实际开始不早于睡眠期开始后约6小时，或（ii）多个次要的喹硫平组分，其在即时释放形式中，在随后的醒来期间依次施用睡眠期不早于睡眠期开始后约6小时; 所述次要组分以不足以引起不可接受的镇静程度的抗焦虑有效量施用。

3. 发明申请

WO2008030830A2 SUSTAINED-RELEASE COMPOSITION AND METHOD OF USE THEREOF 审中-公开
标题翻译：持续释放组合物及其使用方法
公开(公告)号：WO2008030830A2
公开(公告)日：2008-03-13
申请号：PCT/US2007/077572
申请日：2007-09-05
申请人： DRUGTECH CORPORATION , BORTZ, Jonathan , GRIMSHAW, Michael , ERKOBONI, David, F. , DICKUS, Michael, F.
发明人： BORTZ, Jonathan , GRIMSHAW, Michael , ERKOBONI, David, F. , DICKUS, Michael, F.
IPC分类号： A61K9/20 , A61K31/198
CPC分类号： A61K31/198 , A61K9/0065 , A61K9/205 , A61K9/2054
摘要： A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.
摘要翻译：提供包含左旋多巴的药物组合物，其以约6至约24小时的剂量间隔以约100至约500mg的单位剂量的左旋多巴施用时，显示足够长的释放期和足够长的停留时间上消化道提供受试者血浆中左旋多巴的谷浓度，其不低于在受试者中观察到不良运动效应的最低阈值浓度。还提供了治疗受试者中帕金森病的方法，其包括以约3至约24小时的剂量间隔以约50至约1000mg的单位剂量的左旋多巴口服施用该组合物。

4. 发明申请

WO2008030830A3 SUSTAINED-RELEASE COMPOSITION AND METHOD OF USE THEREOF 审中-公开
标题翻译：持续释放组合物及其使用方法
公开(公告)号：WO2008030830A3
公开(公告)日：2008-05-29
申请号：PCT/US2007077572
申请日：2007-09-05
申请人： DRUGTECH CORP , BORTZ JONATHAN , GRIMSHAW MICHAEL , ERKOBONI DAVID F , DICKUS MICHAEL F
发明人： BORTZ JONATHAN , GRIMSHAW MICHAEL , ERKOBONI DAVID F , DICKUS MICHAEL F
IPC分类号： A61K9/20 , A61K31/198
CPC分类号： A61K31/198 , A61K9/0065 , A61K9/205 , A61K9/2054
摘要： A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.
摘要翻译：提供了一种包含左旋多巴的药物组合物，当以约6至约24小时的剂量间隔以约100至约500mg的单位剂量的左旋多巴施用时，显示足够长的释放期和足够长的停留时间所述上胃肠道在所述受试者的血浆中提供不低于最小阈值浓度的左旋多巴的谷浓度，在所述最小阈值浓度以下，在所述受试者中观察到不利运动效应。还提供了用于治疗受试者的帕金森氏病的方法，其包括以约3至约24小时的剂量间隔以约50至约1000mg的单位剂量的左旋多巴口服给予受试者这样的组合物。

5. 发明申请

WO2003056655A1 ISOLATION OF MICROWAVE TRANSMISSION LINES 审中-公开
标题翻译：分离微波传输线
公开(公告)号：WO2003056655A1
公开(公告)日：2003-07-10
申请号：PCT/GB2002/005639
申请日：2002-12-12
申请人： BOOKHAM TECHNOLOGY PLC , BENSON, Iain , GRIMSHAW, Michael , CLARKE, Christopher , KIMBER, Eric , LESTER, Tim
发明人： BENSON, Iain , GRIMSHAW, Michael , CLARKE, Christopher , KIMBER, Eric , LESTER, Tim
IPC分类号： H01P3/08
CPC分类号： G02F1/0344 , G02F1/2257
摘要： An optical waveguide (16, 18) is formed over a substrate, with an insulating planarization layer (30) formed adjacent the optical waveguide (16, 18) and level with the top of the waveguide (16, 18). A microwave transmission line (32a, b) is formed over the planarization layer (30) and overlies a top surface of the optical waveguide(16, 18). In this circuit, isolation of a microwave transmission line (32a, b) is provided by forming the line over a planarization layer (30) which fills the space adjacent to an optical waveguide structure (16, 18). The transmission line (32a, b) can then contact electrically the top surface of the waveguide structure (16, 18) but is isolated from the substrate which supports the waveguide (16, 18).
摘要翻译：光波导16,18形成在衬底上，其中邻近光波导16,18形成绝缘平坦化层30，并且与波导16,18的顶部平齐。微波传输线32a，b形成在平坦化之上层30，并且覆盖在光波导16,18的顶表面上。在该电路中，通过在填充与光波导结构16相邻的空间的平坦化层30上形成线来提供微波传输线32a，b的隔离，传输线32a，b然后可以与波导结构16,18的顶表面电接触，但与支撑波导16,18的基板隔离。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式